Literature DB >> 18460031

Malignant melanoma in patients with hereditary nonpolyposis colorectal cancer.

G Ponti1, L Losi, G Pellacani, L Wannesson, A M Cesinaro, T Venesio, C Petti, S Seidenari.   

Abstract

BACKGROUND: Malignant melanoma (MM) is the most aggressive skin cancer. Most MMs are sporadic, and in this setting an association with mismatch repair (MMR) gene mutations, typical of hereditary nonpolyposis colorectal cancer (HNPCC) tumours, has been proposed.
OBJECTIVES: To characterize clinically and/or by molecular biology the patients with MM belonging to a cohort of 60 kindreds with HNPCC. Methods Patients with HNPCC with a diagnosis of MM were studied by immunohistochemistry (IHC) on tumour tissue using antibodies to MLH1, MSH2, p16, beta-catenin and E-cadherin, and by direct sequencing of MMR genes on germline DNA, and BRAF and NRAS on somatic DNA extracted from MM.
RESULTS: Nine cutaneous MMs were detected in the tumour spectrum of eight families with HNPCC. The median age at diagnosis was 46 years. In one HNPCC family the diagnosis of MM was made in two first-degree relatives fitting the clinical definition of familial melanoma. IHC and sequencing analysis showed an MSH2 mutation in one patient with MM.
CONCLUSIONS: Dermatological surveillance should be recommended to families in which MM is diagnosed in at least one member, especially at a young age. The combination of MMR gene mutations and abnormalities of p16 or other molecular pathways is needed to induce melanocytic carcinogenesis in a familial setting as well as in sporadic MM.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18460031     DOI: 10.1111/j.1365-2133.2008.08575.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  7 in total

Review 1.  Lynch syndrome-associated neoplasms: a discussion on histopathology and immunohistochemistry.

Authors:  Jinru Shia; Susanne Holck; Giovanni Depetris; Joel K Greenson; David S Klimstra
Journal:  Fam Cancer       Date:  2013-06       Impact factor: 2.375

2.  Ovarian metastasis from uveal melanoma with MLH1/PMS2 protein loss in a patient with germline MLH1 mutated Lynch syndrome: consequence or coincidence?

Authors:  João Lobo; Carla Pinto; Micaela Freitas; Manuela Pinheiro; Rámon Vizcaino; Esther Oliva; Manuel R Teixeira; Carmen Jerónimo; Carla Bartosch
Journal:  Virchows Arch       Date:  2016-12-03       Impact factor: 4.064

Review 3.  Cervical neuroendocrine tumor in a young female with Lynch Syndrome.

Authors:  Ibraheem Yousef; Fadi Siyam; Lester Layfield; Carl Freter; James R Sowers
Journal:  Neuro Endocrinol Lett       Date:  2014       Impact factor: 0.765

4.  Immunohistochemical mismatch repair proteins expression as a tool to predict the melanoma immunotherapy response.

Authors:  Giovanni Ponti; Giovanni Pellacani; Aldo Tomasi; Roberta Depenni; Monia Maccaferri; Antonio Maiorana; Giulia Orsi; Francesca Giusti; Stefano Cascinu; Marco Manfredini
Journal:  Mol Clin Oncol       Date:  2019-11-07

Review 5.  Risk of breast cancer in Lynch syndrome: a systematic review.

Authors:  Aung Ko Win; Noralane M Lindor; Mark A Jenkins
Journal:  Breast Cancer Res       Date:  2013-03-19       Impact factor: 6.466

Review 6.  DNA mismatch repair system: repercussions in cellular homeostasis and relationship with aging.

Authors:  Juan Cristóbal Conde-Pérezprina; Miguel Ángel León-Galván; Mina Konigsberg
Journal:  Oxid Med Cell Longev       Date:  2012-11-08       Impact factor: 6.543

7.  Clinical and Molecular Features of Skin Malignancies in Muir-Torre Syndrome.

Authors:  Dario Simic; Reinhard Dummer; Sandra N Freiberger; Egle Ramelyte; Marjam-Jeanette Barysch
Journal:  Genes (Basel)       Date:  2021-05-20       Impact factor: 4.096

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.